Paul Herzich - Dec 2, 2023 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role: Chief Technology Officer
Signature: /s/ David Tyronne Howton as attorney-in-fact for Paul Herzich
Stock symbol: SLDB
Transactions as of: Dec 2, 2023
Transactions value $: -$8,232
Form type: 4
Date filed: 12/5/2023, 02:31 PM
Previous filing: Dec 5, 2022
Next filing: Feb 16, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SLDB	Common Stock	Options Exercise		+7.24K			7.24K	Dec 2, 2023	Direct	F1
transaction	SLDB	Common Stock	Sale	-$8.23K	-2.97K	-41.01%	$2.77	4.27K	Dec 4, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SLDB	Restricted Stock Units	Options Exercise	$0	-7.24K	-25%	$0.00	21.7K	Dec 2, 2023	Common Stock	7.24K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
F2	This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).
F3	The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.